Herline-Killian, K., Pauers, M. M., Lipponen, J. E., Zrzavy, M. A., Gouveia Roque, C., McCurdy, E. P., Chung, K. M., & Hengst, U. (2025). Modulation of CREB3L2-ATF4 heterodimerization via proteasome inhibition and HRI activation in Alzheimer’s disease pathology. Cell Death & Disease, 16(1). https://doi.org/10.1038/s41419-025-07586-0

Lawong, A., Gahalawat, S., Ray, S., Ho, N., Han, Y., Ward, K. E., Deng, X., Chen, Z., Kumar, A., Xing, C., Hosangadi, V., Fairhurst, K. J., Tashiro, K., Liszczak, G., Shackleford, D. M., Katneni, K., Chen, G., Saunders, J., Crighton, E., … Phillips, M. A. (2024). Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria. Cell Chemical Biology, 31(8), 1503-1517.e19. https://doi.org/10.1016/j.chembiol.2024.07.001

Xie, S. C., Metcalfe, R. D., Mizutani, H., Puhalovich, T., Hanssen, E., Morton, C. J., Du, Y., Dogovski, C., Huang, S.-C., Ciavarri, J., Hales, P., Griffin, R. J., Cohen, L. H., Chuang, B.-C., Wittlin, S., Deni, I., Yeo, T., Ward, K. E., Barry, D. C., … Tilley, L. (2021). Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences, 118(39). https://doi.org/10.1073/pnas.2107213118